Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claims evaluated against the provided FDA label excerpts are fully supported: Vyvanse has a high potential for abuse/misuse/addiction leading to overdose and death, with increased risk at higher doses and unapproved methods such as snorting or injection.
Category Scores
Accurate Statements
VYVANSE has a high potential for abuse/misuse/addiction.
Supported by Section 5.1 and Section 9.2 stating VYVANSE has a high potential for abuse and misuse and can lead to substance use disorder including addiction.
Abuse/misuse can lead to overdose and death.
Supported by Section 5.1 and Section 9.2 stating misuse/abuse of CNS stimulants including VYVANSE can result in overdose and death.
Risk is increased at higher doses.
Supported by Section 5.1 and Section 9.2 stating overdose/death risk is increased with higher doses.
Risk is increased with unapproved routes such as snorting or injection.
Supported by Section 5.1 and Section 9.2 explicitly mentioning unapproved methods of administration such as snorting or injection.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement is directly consistent with the label’s abuse/misuse warning and overdose/death risk language; no contradictory or unsupported safety claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement